Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Novo Nordisk will pay $54 per share in cash (or an aggregated value of $4.7 billion) at closing. In addition, Akero shareholders will receive a non-transferable CVR entitling holders to a potential ...

A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little STOCKHOLM (Reuters) -Novo Nordisk said on ...

Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with ...

Novo Nordisk NOVO.B-0.96%decrease; red down pointing triangle agreed to acquire Akero Therapeutics AKRO-0.35%decrease; red down pointing triangle for up to $5.2 billion in cash. Under the terms of the ...

Novo Nordisk said Thursday it was buying US biotech firm Akero Therapeutics, which is developing treatments for a number of metabolic diseases, for $4.7 billion. The Danish firm, the maker of ...

Akero Therapeutics (NASDAQ:AKRO) has entered into a definitive agreement to be acquired by Novo Nordisk (NVO) for up to $5.2 billion in cash, it said on Thursday, boosting shares ahead of the market ...

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "United States Rapid Acting Insulin Market Report by Product, Indication, Distribution Channel, States and Company Analysis, 2025-2033" report has been ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It is the second deal for a Bay ...

Carolina Wealth Advisors, LLC added 102,629 shares of Novo Nordisk A/S, an estimated $6.01 million trade based on the average price for Q3 2025. The trade represented 2.6% of reportable AUM for the ...